Si L - Search Results

1

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.

Si L, Zhang X, Shin SJ, Fan Y, Lin CC, Kim TM, Dechaphunkul A, Maneechavakajorn J, Wong CS, Ilankumaran P, Lee DY, Gasal E, Li H, Guo J. Si L, et al. Eur J Cancer. 2020 Aug;135:31-38. doi: 10.1016/j.ejca.2020.04.044. Epub 2020 Jun 10. Eur J Cancer. 2020. PMID: 32534242 Clinical Trial.

2

[Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].

Cui CL, Chi ZH, Yuan XQ, Lian HY, Si L, Guo J. Cui CL, et al. Among authors: si l. Ai Zheng. 2008 Aug;27(8):845-50. Ai Zheng. 2008. PMID: 18710619 Free article. Clinical Trial. Chinese.

3

Large-scale analysis of KIT aberrations in Chinese patients with melanoma.

Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J. Kong Y, et al. Among authors: si l. Clin Cancer Res. 2011 Apr 1;17(7):1684-91. doi: 10.1158/1078-0432.CCR-10-2346. Epub 2011 Feb 15. Clin Cancer Res. 2011. PMID: 21325067

4

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.

Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J. Chi Z, et al. Among authors: si l. BMC Cancer. 2011 Feb 25;11:85. doi: 10.1186/1471-2407-11-85. BMC Cancer. 2011. PMID: 21349197 Free PMC article.

5

A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.

Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, Tang B, Guo J. Mao L, et al. Among authors: si l. Eur J Cancer. 2011 Jul;47(10):1498-503. doi: 10.1016/j.ejca.2011.03.019. Epub 2011 Apr 13. Eur J Cancer. 2011. PMID: 21493058 Clinical Trial.

6

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S. Guo J, et al. Among authors: si l. J Clin Oncol. 2011 Jul 20;29(21):2904-9. doi: 10.1200/JCO.2010.33.9275. Epub 2011 Jun 20. J Clin Oncol. 2011. PMID: 21690468 Clinical Trial.

7

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J. Si L, et al. Eur J Cancer. 2012 Jan;48(1):94-100. doi: 10.1016/j.ejca.2011.06.056. Epub 2011 Jul 23. Eur J Cancer. 2012. PMID: 21788131

8

Major response to everolimus in melanoma with acquired imatinib resistance.

Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C, Sheng X, Li S, Dai J, Yu W, Guo J. Si L, et al. J Clin Oncol. 2012 Feb 1;30(4):e37-40. doi: 10.1200/JCO.2011.37.9644. Epub 2011 Dec 12. J Clin Oncol. 2012. PMID: 22162580 No abstract available.

9

C-kit-mutated melanomas: the Chinese experience.

Si L, Guo J. Si L, et al. Curr Opin Oncol. 2013 Mar;25(2):160-5. doi: 10.1097/CCO.0b013e32835dafcc. Curr Opin Oncol. 2013. PMID: 23299198

10

[Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion].

Yang SY, Cui CL, Chi ZH, Si L, Sheng XN, Mao LL, Lian B, Guo J. Yang SY, et al. Among authors: si l. Zhonghua Yi Xue Za Zhi. 2012 Nov 13;92(42):2998-3000. doi: 10.3760/cma.j.issn.0376-2491.2012.42.013. Zhonghua Yi Xue Za Zhi. 2012. PMID: 23328294 Clinical Trial. Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,211 results

Search Page

Filters